What's in German Diabetes Center's pipeline?

German Diabetes Center has 6 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with German Diabetes Center's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/german-diabetes-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

German Diabetes Center — Portfolio Competitive Intelligence Brief

German Diabetes Center pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Area
Fat/Inflammation effects	Fat/Inflammation effects	marketed	Diabetes
fat orally	fat orally	marketed
intransal insulin	intransal insulin	marketed

Therapeutic area mix

Diabetes · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for German Diabetes Center:

Cite this brief

Drug Landscape (2026). German Diabetes Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/german-diabetes-center. Accessed 2026-05-16.